貝達藥業(300558.SZ)：控股子公司與EYPT簽訂Vorolanib許可協議
格隆匯2月5日丨貝達藥業(300558.SZ)公佈，2020年2月3日，公司控股子公司Equinox Sciences, LLC(以下簡稱“Equinox”)與EyePoint Pharmaceuticals, Inc.(NASDAQ：EYPT)簽署了《獨佔許可協議》，獨家授權EYPT以局部注射方式開發酪氨酸激酶抑制劑Vorolanib(CM082)來治療濕性年齡相關性黃斑變性(w-AMD)等眼部疾病。
EYPT是一家專業的生物製藥公司，致力於開發和商業化針對眼部疾病的創新治療方案，以幫助改善嚴重眼部疾病患者的生活，其股票於美國NASDAQ證券交易所上市交易。該公司目前有DEXYCU®、YUTIQ®兩種商業化產品，其中DEXYCU®是治療術後炎症的眼內產品，YUTIQ®是對影響眼球后段的慢性非傳染性葡萄膜炎進行為期三年治療的產品。
根據《獨佔許可協議》條款，EYPT將向Equinox支付100萬美元的首付款，並在達到開發里程碑事件後支付里程碑款項和商業化後支付銷售提成費。EYPT負責新治療方案EYP-1901的開發和中國(包括香港、澳門和台灣)區域外的全球商業化，用於治療濕性年齡相關性黃斑變性(w-AMD)、糖尿病視網膜病變(DR)和視網膜靜脈阻塞(RVO)。EYP-1901是將Vorolanib和Bioerodable Durasert™技術相結合，形成一種新的治療方案，Bioerodable Durasert™技術是一種可注射、緩釋的玻璃體內給藥系統，有效期可達6個月。目前，EYPT和美國食品藥品監督管理局(FDA)已召開B類IND前會議，明確了EYP-1901的Ⅰ期臨牀試驗方案。
Vorolanib是針對VEGFR和PDGFR靶點的多靶點受體酪氨酸激酶(RTKs)抑制劑，可抑制新生血管生成及腫瘤生長，並能克服同類靶向藥常見的高毒副作用。公司通過控股子公司Equinox擁有Vorolanib眼科適應症的海外權益，通過控股子公司Xcovery Holdings, Inc.擁有Vorolanib腫瘤適應症的海外權益，通過全資子公司卡南吉醫藥科技(上海)有限公司擁有Vorolanib全部適應症的中國權益。
公司表示，該次許可協議的簽訂是公司新藥Vorolanib境外眼科適應症開發和商業化的重要一步，有望為嚴重眼科疾病患者(包括w-AMD、DR和RVO)提供一種新的局部注射治療方案，短期內對公司經營不會產生影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
